Results 21 to 30 of about 18,455 (220)

New Frontiers in Molecular Imaging Using Peptide-Based Radiopharmaceuticals for Prostate Cancer

Frontiers in Chemistry, 2020
The high incidence of prostate cancer (PCa) increases the need for progress in its diagnosis, staging, and precise treatment. The overexpression of tumor-specific receptors for peptides in human cancer cells, such as gastrin-releasing peptide receptor ...
Xin Li, Huawei Cai, Xiaoai Wu, Li Li, Haoxing Wu, Rong Tian   +5 more
doaj   +1 more source

Somatostatin Analogues in the Treatment of Neuroendocrine Tumors: Past, Present and Future [PDF]

, 2019
In recent decades, the incidence of neuroendocrine tumors (NETs) has steadily increased. Due to the slow-growing nature of these tumors and the lack of early symptoms, most cases are diagnosed at advanced stages, when curative treatment options are no ...
Amthauer, Holger, Jann, Henning, Kayser, Antonin, Roderburg, Christoph, Stueven, Anna Kathrin, Tacke, Frank, Wetz, Christoph, Wiedenmann, Bertram, Wree, Alexander   +8 more
core   +1 more source

Peptide Receptor Radionuclide Therapy – Prospects for Personalised Treatment [PDF]

Clinical Oncology, 2021
Peptide receptor radionuclide therapy is a type of molecular radiotherapy that has been used in the treatment of patients with neuroendocrine tumours for over two decades. It is not until recently, however, that it has achieved regulatory approval. The currently approved treatment regimen is a one-size-fits-all scheme, i.e. all patients receive a fixed
A, Sundlöv, K, Sjögreen-Gleisner
openaire   +2 more sources

RADIONUCLIDE IMAGING AND THERAPY OF NEUROENDOCRINE TUMOURS

Journal of Cancer and Allied Specialties, 2015
The incidence and prevalence of neuroendocrine tumours (NETs) are on the rise. Although NETs are a heterogeneous group of tumours, they have some similar properties, for example, that they can concentrate neuroamines and tend to have a high degree of ...
Shaunak Navalkissoor, Gopinath Gnanasegaran   +1 more
doaj   +1 more source

Therapeutic sequences in patients with grade 1−2 neuroendocrine tumors (NET): an observational multicenter study from the ELIOS group [PDF]

, 2019
Purpose: Many different treatments are suggested by guidelines to treat grade 1−2 (G1−G2) neuroendocrine tumors (NET). However, a precise therapeutic algorithm has not yet been established.
Badalamenti, G., Bianco, A., Colao, A., De Divitiis, C., Di Maio, S., Di Sarno, A., Dolce, P., Faggiano, A., Guarnotta, V., Leo, S., Mocerino, C., Modica, R., Ottaviano, M., Palmieri, G., Puliafito, I., Riccardi, F., Tafuto, S., Tozzi, L.   +17 more
core   +1 more source

Targeted radiotherapy of neuroblastoma: future directions [PDF]

, 2017
No abstract ...
Gaze, Mark N., Mairs, Robert, Nile, Donna L., Rae, Colin, Tesson, Mathias   +4 more
core   +2 more sources

Phase 3 Trial of 177Lu-Dotatate for Midgut Neuroendocrine Tumors [PDF]

, 2017
Background Patients with advanced midgut neuroendocrine tumors who have had disease progression during first-line somatostatin analogue therapy have limited therapeutic options.
Al‐nahhas, A, Ansquer, C, Anthony, L, Azevedo, I, Baudin, E, Baum, Rp, Baum, Rp, Benson, A, Benson, Ab, Berlin, J, Berlin, J, Bodei, L, Brianzoni, E, Bushnell, D, Bushnell, D, Caplin, M, Caplin, M, Chasen, B, Chiara Grana, M, Courbon, F, DELLE FAVE, Gianfranco, Delpassand, E, Delpassand, E, El Haddad, G, Erion, Jl, Freemantle, N, Garbus, S, Giammarile, F, Grande, E, Grande, E, Grossman, A, Hendifar, A, Hendifar, A, Hobday, T, Hobday, T, Jacene, H, Krenning, E, Kulkarni, Hr, Kulke, M, Kulke, Mh, Kunz, Pl, Kvols, L, Kwekkeboom, D, Lebtahi, R, Lopera Sierra, M, Manoharan, P, Mariani, G, Metz, D, Mittra, E, Mittra, E, Mora, J, Mora, J, Morse, M, O'Dorisio, Tm, Pavel, M, Pavel, M, Reed, N, Reed, N, Rindi, G, Ruszniewski, P, Ruszniewski, P, Santoro, P, Scheidhauer, K, Schipper, M, Seregni, E, Seregni, E, Severi, S, Srirajaskanthan, R, Srirajaskanthan, R, Strosberg, J, Strosberg, J, Sundin, A, Taieb, D, Thevenet, T, Van Cutsem, E, Van Cutsem, E, Weber, M, Wolin, E, Wolin, E, Yao, J, Yao, J., Öberg, K, Öberg, K   +82 more
core   +1 more source

Peptide Receptor Radionuclide Therapy [PDF]

, 2020
Peptide receptor radionuclide therapy (PRRT) uses, as a therapeutic target, the overexpression of somatostatin receptors (SSTRs) in neuroendocrine tumours (NETs). The radiopharmaceutical contains generally a somatostatin analogue, which binds somatostatin receptors, and a linking molecule (chelator), which binds the radioisotope: most commonly Lutetium-
openaire   +2 more sources

Evaluation of a PACAP Peptide Analogue Labeled with (68)Ga Using Two Different Chelating Agents. [PDF]

, 2016
OBJECTIVE: The authors have conjugated chelating agents (DOTA and NODAGA) with a peptide (pituitary adenylate cyclase-activating peptide [PACAP] analogue) that has a high affinity for VPAC1 receptors expressed on cancer cells.
Chen, Chang-Po, Kumar, Pardeep, Mehta, Neil, Paudyal, Bishnuhari, Thakur, Mathew L., Tripathi, Sushil Kumar, Wickstrom, Eric   +6 more
core   +2 more sources

New Developments in Peptide Receptor Radionuclide Therapy [PDF]

Journal of Nuclear Medicine, 2018
Peptide Receptor Radionuclide Therapy (PRRT) is an established treatment for non-operable or metastatic neuroendocrine neoplasms that express highly and frequently somatostatin receptors. More generally, PRRT is an attractive therapy option for delivering cytotoxic radiation to tumor cells through specific binding of a radiolabeled peptide to a ...
Guillaume P, Nicolas, Alfred, Morgenstern, Margret, Schottelius, Melpomeni, Fani   +3 more
openaire   +2 more sources